Summary
- The federal government is taking action against pharmacy benefit managers (PBMs) to address high insulin prices
- The FTC lawsuit targets top PBMs for creating a “perverse drug rebate system” that drives up the cost of insulin
- Over the last two decades, the cost of insulin has increased by 600%, leading to affordability issues and health risks for many Americans with diabetes
- Efforts have been made to lower insulin costs, including legislation capping out-of-pocket expenses and commitments from major insulin manufacturers